Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits.
Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S. Yoshida T, et al. Among authors: ichikawa s. Oncotarget. 2018 Jan 11;9(11):9975-9991. doi: 10.18632/oncotarget.24160. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515784 Free PMC article.
Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S, Chiba T, Yoshida T, Ri M, Iida S, Matsuda A, Ichikawa S. Kitahata S, et al. Among authors: ichikawa s. Org Lett. 2016 May 6;18(9):2312-5. doi: 10.1021/acs.orglett.6b01053. Epub 2016 Apr 28. Org Lett. 2016. PMID: 27123978
Modulation of proteasome subunit selectivity of syringolins.
Tatsumi K, Kitahata S, Komatani Y, Katsuyama A, Yakushiji F, Ichikawa S. Tatsumi K, et al. Among authors: ichikawa s. Bioorg Med Chem. 2024 May 15;106:117733. doi: 10.1016/j.bmc.2024.117733. Epub 2024 Apr 27. Bioorg Med Chem. 2024. PMID: 38704960
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Ohmachi K, et al. Among authors: ichikawa s. Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19. Int J Hematol. 2018. PMID: 30027429 Clinical Trial.
1,212 results